河北医科大学学报 ›› 2023, Vol. 44 ›› Issue (9): 1037-1042.doi: 10.3969/j.issn.1007-3205.2023.09.009

• • 上一篇    下一篇

血清白细胞介素23、血管内皮生长因子与宫颈癌患者临床预后的相关性

  

  1. 河北省唐山市妇幼保健院妇科，河北 唐山 063000

  • 出版日期:2023-09-25 发布日期:2023-10-12
  • 作者简介:汪莹（1984-），女，河北唐山人，河北省唐山市妇幼保健院副主任医师，医学学士，从事妇科疾病诊治研究。
  • 基金资助:
    河北省医学科学研究课题计划（20221756）

Correlation between serum interleukin-23, vascular endothelial growth factor and clinical prognosis in patients with cervical cancer

  1. Department of Gynecology Tangshan, Maternal and Child Health Care Hospital, Hebei Province, Tangshan 063000, China

  • Online:2023-09-25 Published:2023-10-12

HTML

PDF (PC)

118

摘要： 目的  探讨血清白细胞介素（interleukin，IL）23、血管内皮生长因子（vascular endothelial growth factor，VEGF）与宫颈癌患者临床预后的相关性。
方法  选取医院收治的宫颈癌患者410例作为研究对象，调查患者基线资料，并检测血清IL-23、VEGF等相关指标；随访1年，以复发作为临床预后的判定标准，采用COX回归分析血清IL-23、VEGF水平与患者临床预后的相关性；绘制ROC曲线和决策曲线，分析血清IL-23、VEGF水平预测患者临床预后的价值。
结果  410例宫颈癌患者随访结束时，有62例复发，复发率为15.12%；预后不良组血清IL-23、VEGF、糖类抗原（carbohydrate antigen，CA）125、鳞状细胞癌抗原（squamous cell carcinoma antigen，SCC-Ag）水平均高于预后良好组，差异有统计学意义（P＜0.05）；2组年龄、体重指数、孕次、产次、国际妇产科联盟（International Federation of Gynecology and Obstetrics，FIGO）分期、病理类型、肿瘤直径、血红蛋白（hemoglobin，Hb）、白细胞计数（white blood cell，WBC）、红细胞计数（red blood cell count，RBC）及血小板（blood platelet，PLT）水平比较，差异无统计学意义（P＞0.05）；经COX回归分析显示，血清SCC-Ag、CA125、IL-23、VEGF水平与宫颈癌患者临床预后有关（P＜0.05）；绘制受试者工作特征曲线（receiver operating characteristi，ROC）显示，血清IL-23、VEGF水平单独及联合预测宫颈癌患者临床预后的曲线下面积（area under curve，AUC）均＞0.7，均有一定预测价值，但以联合预测的价值最好；决策曲线分析结果显示，在0.10~0.45、0.49~0.59、0.61~0.77的阈值概率区间，血清IL-23、VEGF水平联合预测宫颈癌临床预后的净收益率优于单一血清IL-23、VEGF水平。
结论  血清IL-23、VEGF水平与宫颈癌患者临床预后相关。


关键词: 宫颈肿瘤, 白细胞介素23, 血管内皮生长因子A

Abstract: Objective  To investigate the correlation between serum interleukin-23 (IL-23), vascular endothelial growth factor (VEGF) and clinical prognosis in patients with cervical cancer. 
Methods  A total of 410 patients with cervical cancer treated in the hospital were selected as the research subjects. The baseline data of patients were investigated, and serum IL-23, VEGF and other related indicators were detected. The patients were followed up for 1 year. Recurrence was taken as the criterion of clinical prognosis. The correlation between the levels of serum IL-23 and VEGF and the clinical prognosis was analyzed by COX regression, and the ROC curve and decision-making curve were drawn to analyze the value of serum IL-23 and VEGF levels in predicting the clinical prognosis of patients. 
Results  At the end of the follow-up of 410 patients with cervical cancer, 62 cases recurred, and the recurrence rate was 15.12%. The levels of serum IL-23, VEGF, carbohydrate antigen (CA) 125 and squamous cell carcinoma antigen (SCC-Ag) in the poor prognosis group were higher than those in the good prognosis group, and the difference was statistically significant (P＜0.05). There was no statistical significant difference between two groups in age, body mass index, pregnancy times, parity, International Federation of Gynecology and Obstetrics (FIGO) stage, pathological type, tumor diameter, hemoglobin (Hb), white blood cell count (WBC), red blood cell count (RBC) and platelet (PLT) levels (P＞0.05). COX regression analysis showed that the levels of serum SCC Ag, CA125, IL-23 and VEGF were related to the clinical prognosis of cervical cancer patients (P＜0.05). The receiver operating characteristic (ROC) curve revealed that the area under the ROC curve (AUC) of serum IL-23 and VEGF level alone and in combination in predicting the clinical prognosis of cervical cancer patients was >0.7, showing certain predictive value, but combined prediction was of the highest value. The results of decision curve analysis showed that in the threshold probability interval of 0.1-0.45, 0.49-0.59 and 0.61-0.77, the net benefit rate of serum IL-23 and VEGF in combination to predict the clinical prognosis of cervical cancer was better than that of serum IL-23 and VEGF alone. 
Conclusion  The levels of serum IL-23 and VEGF are related with the clinical prognosis of patients with cervical cancer. 


Key words: uterine cervical neoplasms, interleukin-23, vascular endothelial growth factor A

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发